HighMark Wealth Management’s Quest Diagnostics DGX Stock Holding History

HighMark Wealth Management’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-236	Closed	-$36.9K	–	605
2022 Q4	$36.9K	Buy	236 +1	+0.4%	+$144	0.03%	120
2022 Q3	$29K	Buy	235 +1	+0.4%	+$132	0.02%	130
2022 Q2	$31K	Buy	234 +2	+0.9%	+$273	0.02%	126
2022 Q1	$32K	Buy	232 +1	+0.4%	+$139	0.02%	132
2021 Q4	$40K	Buy	231 +1	+0.4%	+$152	0.03%	131
2021 Q3	$33K	Buy	230 +1	+0.4%	+$146	0.02%	140
2021 Q2	$30K	Buy	229 +1	+0.4%	+$131	0.02%	153
2021 Q1	$29K	Buy	228 +1	+0.4%	+$123	0.02%	141
2020 Q4	$27K	Buy	227 +1	+0.4%	+$122	0.02%	141
2020 Q3	$26K	Buy	226 +1	+0.4%	+$118	0.02%	143
2020 Q2	$26K	Buy	225 +1	+0.4%	+$106	0.03%	115
2020 Q1	$17K	Buy	224 +2	+0.9%	+$207	0.02%	119
2019 Q4	$23K	Buy	+222	New	+$23.2K	0.02%	125

Other funds holding DGX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

HighMark Wealth Management's DGX Position: Q1 2023 in Review

HighMark Wealth Management sold out of Quest Diagnostics (DGX) in Q1 2023, closing a stake of 236 shares — an estimated $36.9K sold.

HighMark Wealth Management first reported a position in DGX in Q4 2019 and held it in 13 quarters. The position peaked at $40K in Q4 2021. 834 funds tracked by Wall St. Rank hold DGX as of Q1 2023.

HighMark Wealth Management reported no remaining Quest Diagnostics position as of Q1 2023 after selling out during the quarter.
HighMark Wealth Management sold 236 Quest Diagnostics shares in Q1 2023, an estimated $36.9K.
HighMark Wealth Management first reported a position in Quest Diagnostics in Q4 2019 and held it in 13 quarters.
HighMark Wealth Management's Quest Diagnostics position peaked at $40K in Q4 2021.
834 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2023.

Based on HighMark Wealth Management's 13F filing for Q1 2023, filed 21 Apr 2023.